These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27241723)

  • 1. Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant.
    HogenEsch H; Dunham A; Burlet E; Lu F; Mosley YC; Morefield G
    J Appl Toxicol; 2017 Feb; 37(2):222-230. PubMed ID: 27241723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes.
    Morefield G; Touhey G; Lu F; Dunham A; HogenEsch H
    Vaccine; 2014 Jun; 32(30):3810-5. PubMed ID: 24837509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
    Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
    JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.
    Reynolds S; Pandey M; Dooley J; Calcutt A; Batzloff M; Ozberk V; Mills JL; Good M
    Sci Rep; 2021 Jan; 11(1):127. PubMed ID: 33420258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
    Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
    Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
    Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
    Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.
    Destexhe E; Prinsen MK; van Schöll I; Kuper CF; Garçon N; Veenstra S; Segal L
    J Pharmacol Toxicol Methods; 2013; 68(3):367-73. PubMed ID: 23624216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
    Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
    J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose site reactions and related findings after vaccine administration in safety studies.
    Baldrick P
    J Appl Toxicol; 2016 Aug; 36(8):980-90. PubMed ID: 26968331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
    Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
    Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant.
    Lu F; Hogenesch H
    Vaccine; 2013 Aug; 31(37):3979-86. PubMed ID: 23770306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits.
    Giordano G; Segal L; Prinsen M; Wijnands MV; Garçon N; Destexhe E
    J Appl Toxicol; 2017 Feb; 37(2):132-141. PubMed ID: 27172098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new recombinant SsnA protein combined with aluminum hydroxide protects mouse against Streptococcus suis.
    Gómez-Gascón L; Cardoso-Toset F; Amarilla PS; Tarradas C; Carrasco L; Olaya-Abril A; Jiménez-Munguía I; Rodríguez-Ortega MJ; Luque I
    Vaccine; 2014 Dec; 32(51):6992-6999. PubMed ID: 25454868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
    Kamtchoua T; Bologa M; Hopfer R; Neveu D; Hu B; Sheng X; Corde N; Pouzet C; Zimmermann G; Gurunathan S
    Vaccine; 2013 Jan; 31(2):327-33. PubMed ID: 23153437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant.
    Levesque PM; Foster K; de Alwis U
    Hum Vaccin; 2006; 2(2):74-7. PubMed ID: 17012880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.
    Burlet E; HogenEsch H; Dunham A; Morefield G
    AAPS J; 2017 May; 19(3):875-881. PubMed ID: 28283948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.